GlassScriptPhysician profile
Manisha Malhotra
NPI 1780614065
$3,069.43
in general payments reported to CMS, 2019-2025
23 companies · $603 in 2025
The $603 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $314 · 2021: $163 · 2022: $191 · 2023: $310 · 2024: $585 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,497.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $693.31 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $520.47 | 2019-2025 | |
| Lilly USA, LLC | $513.11 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $246.35 | 2019-2025 | Shingrix, Bexsero |
| Exact Sciences Corporation | $177.69 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $118.81 | 2020-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $113.26 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $93.50 | 2019-2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Kowa Pharmaceuticals America, INC. | $91.31 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.97 | 2019-2021 | |
| Adlon Therapeutics L.P. | $79.89 | 2019 | |
| Kaleo, INC. | $55.39 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.47 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $48.75 | 2019 | |
| Avion Pharmaceuticals | $29.14 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $23.64 | 2023 | Heplisav-B |
| Hologic Sales and Service, LLC | $21.04 | 2019 | |
| Janssen Pharmaceuticals, INC | $19.94 | 2020 | |
| Currax Pharmaceuticals LLC | $18.00 | 2025 | Contrave |
| Biohaven Pharmaceutical Holding Company LTD. | $17.90 | 2022 | |
| Ironshore Pharmaceuticals INC. | $16.88 | 2019 | |
| Bausch Health US, LLC | $14.55 | 2019 | |
| Sanofi Pasteur INC. | $14.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manisha Malhotra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.